China
Africa
Explore chapters and articles related to this topic
Motion Sickness/Travel Sickness/Car Sickness
Published in Charles Theisler, Adjuvant Medical Care, 2023
OTC Products: Prevention is the key, so meclizine (Bonine, Antivert) or Ranitidine (Zantac) may be used in the evening before travel to obtain adequate blood levels. Meclizine is often used in a dosage of 25 mg every six hours. Two doses are to be taken the night before travel and the regimen should be continued throughout the actual travel time.1 If not taken the night before, meclizine 50 mg can be taken orally one hour before departure.2 Ranitidine 150 mg should be taken at bedtime the night before travel and again in the morning.1 Recently, the FDA alerted the public that the drug ranitidine (Zantac) can contain a cancer-causing impurity called N-nitrosodimethylamine (NDMA). No recall of the drug has been issued.
Gastrointestinal diseases and pregnancy
Published in Hung N. Winn, Frank A. Chervenak, Roberto Romero, Clinical Maternal-Fetal Medicine Online, 2021
Murtaza Arif, Anjana Sathyamurthy, Jessica Winn, Jamal A. Ibdah
Histamine-2 receptor antagonists: All histamine-2 receptor antagonists (H2RAs) including cimetidine, ranitidine, famotidine, and nizatidine are classified as FDA pregnancy category B. H2RAs have been recently replaced by proton pump inhibitors for treatment of reflux esophagitis in nonpregnant patients; however, in pregnant patients with GERD, H2RAs are the most commonly used and safest medications for those not responding to lifestyle modifications and antacids. Generally, 8 ormore weeks of therapy is required to produce complete healing, and recurrences are frequent when medication is discontinued. In a study, efficacy of ranitidine once or twice daily was compared with placebo in pregnant women (20). Only ranitidine 150mg twice daily demonstrated significant relief in symptoms and reduction in the use of antacids. No adverse pregnancy or fetal outcomes were noted. A surveil-lance study in the United States found no increase in the incidence of congenital anomalies among infants exposed to various H2RAs including ranitidine, cimetidine, and famoti-dine (21). Ranitidine is usually the preferred H2RA during pregnancy because of the absence of teratogenicity in animal studies and documented efficacy in pregnancy.
Bariatric surgery
Published in Mark Davenport, James D. Geiger, Nigel J. Hall, Steven S. Rothenberg, Operative Pediatric Surgery, 2020
Lindel C.K. Dewberry, Thomas H. Inge
Initially, the diet is essentially a protein-rich liquid diet. Dietary advancement after the first month is a methodical process of introducing new items of gradually increasing complexity, toward the goal of a well-balanced, small portion (approximately one cup per meal) diet which ensures a daily intake of 0.5–1 g of protein per kg of ideal weight. Non-steroidal anti-inflammatory medications should be avoided to reduce the risk of intestinal ulceration and bleeding most commonly seen in RYGBP. Ranitidine is prescribed for 6 months postoperatively with some SG patients requiring the transition to a proton-pump inhibitor due to the increased incidence of reflux-type symptoms. Postoperative vitamin and mineral supplementation typically consists of two pediatric chewable multivitamins, a calcium supplement, and an iron supplement for menstruating females. B-complex vitamins are supplemented beyond that which is contained in multivitamin preparations, primarily to augment thiamine and folate supplementation, due to severe complications if deficiency develops.
Protective effect of standardised fruit extract of Garcinia cowa Roxb. ex Choisy against ethanol induced gastric mucosal lesions in Wistar rats
Published in Annals of Medicine, 2021
Prakash Chandra Gupta, Ashish Kar, Nisha Sharma, Prashant Kumar Singh, Naba Kumar Goswami, Satyanshu Kumar
All the standard and tested drugs were suspended in 1% carboxymethyl cellulose (CMC) and administered orally (by gavage). Test drug (GCE) in doses of 200 mg/kg b.w. (morning and evening with total 400 mg/kg b.w./day) and 400 mg/kg b.w. (morning and evening with total 800 mg/kg b.w./day) and standard drug H2 receptor blocker ranitidine (RAN) in the dose of 50 mg/kg b.w. (morning and evening with total 100 mg/kg b.w./day) were administered orally with the help of an orogastric tube twice daily for 5 days for acute ulcer protective studies in ethanol-induced ulcer model. The selected doses of GCE were determined based on the acute oral toxicity test discussed under paragraph 3.4. The dose of ranitidine was selected based on the well-established dose-response curve previously published and reported studies [36]. The Control group of animals received 1% carboxymethyl cellulose in distilled water.
Isatuximab for the treatment of relapsed/refractory multiple myeloma
Published in Expert Opinion on Biological Therapy, 2020
Paul G. Richardson, Meral Beksaç, Ivan Špička, Joseph Mikhael
In the ICARIA-MM and IKEMA Phase III trials, the majority of IRs occurred at first infusion and were reversible [47,55]. Standard prophylaxis for isatuximab IRs consisted of acetaminophen (650–1000 mg oral), ranitidine (50 mg IV or equivalent), and diphenhydramine (25–50 mg IV or equivalent). However, on 1 April 2020, the FDA requested the removal of all ranitidine products from the market and is no longer available [57]. As so, ranitidine is no longer recommended and has been removed from the investigator brochure. Dexamethasone 40 mg QW (or 20 mg QW in patients ≥75 years) via oral or IV was administered as part of premedication and study treatment. Patients who did not experience an IR upon their first four isatuximab administrations had their need for subsequent premedications reconsidered as per investigator judgment. No post-infusion corticosteroid or bronchodilator prophylaxis was mandated during isatuximab clinical studies [38,42,43,47,55,58].
Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction
Published in Platelets, 2019
Joakim Alfredsson, Eva Swahn, Kerstin M Gustafsson, Magnus Janzon, Lena Jonasson, Elisabeth Logander, Lennart Nilsson, Tomas L. Lindahl
We included 77 patients; median age was 66 years, 74% were male, 29% were smokers, 12% had diabetes, 17% had a history of myocardial infarction (MI) and 16% had a history of revascularization with PCI or coronary artery by-pass grafting (9% and 7%, respectively). A majority of the patients were admitted with STEMI, (60%), all but one were catheterized, 90% underwent PCI and 82% had a stent implanted (Table I). During PCI, 58% were treated with a GP IIb/IIIa-inhibitor (abciximab). There were no significant differences in pharmacological treatment from discharge to 6-month follow-up. Importantly, all patients were discharged with DAPT (clopidogrel and aspirin) and continued on DAPT at least 6 months. (Table II) A total of 15 patients were discharged with a proton pump inhibitor (PPI) or H2 antagonist. Nine received pantoprazole (recommended PPI with clopidogrel treatment), three ranitidin, two omeprazol and one lanzoprazol. The majority of the patients remained on the same treatment over 6-month follow-up. Of the two patients discharged with omeprazole, one was on omeprazole for the duration of the follow-up with no change in platelet aggregation category (LPR at both time-points) and one stopped treatment before 6-month follow-up (LPR at 8 days and optimal response at 6 months). In addition, one patient discharged with ranitidine changed to omeprazole during follow-up, with no change in aggregation category (optimal response both at 8 days and 6 months).